Czech Breakthrough in Medicine: H2 Global Group Receives Regulatory Approval for Hydrogen Clinical Study — New Era in Alzheimer’s Therapy Begins

Czech Breakthrough in Medicine: H2 Global Group Receives Regulatory Approval for Hydrogen Clinical Study — New Era in Alzheimer’s Therapy Begins

by | Oct 26, 2025 | Alzheimer, Health, Neurology, Spa

European innovation leader H₂ Global Group today announced that its subsidiary H₂ Medical Technologies has received official approval from The State Institute for Drug Control (SÚKL) to initiate a clinical study focused on molecular hydrogen inhalation therapy for patients with mild cognitive impairment (MCI), an early stage of Alzheimer’s disease.

This milestone marks a historic achievement for Czech and European biotechnology, as it represents Europe’s first fully approved clinical trial investigating non-invasive hydrogen inhalation as a neuroprotective therapy.

From Japanese discovery to Czech clinical practice

The project is based on pioneering research by Professor Shigeo Ohta, co-founder of H₂ Global Group and widely regarded as the founding father of therapeutic hydrogen medicine. Professor Ohta personally transferred his European patent (EP 3701956 B1), titled “Prophylactic or Therapeutic Agent for Dementia,” to the Group.

“Launching a clinical study that directly builds on Professor Ohta’s patent is both an honor and a responsibility,” said PharmDr. Milan Krajíček, co-founder of H₂ Global Group. “This milestone proves that Czech innovation and research have truly a global relevance.”

New hope for Alzheimer’s prevention and treatment

“While several antibody-based drugs have been approved to slow Alzheimer’s progression, there is still no widely available, safe, and effective non-invasive treatment,” said David Maršálek, founder and CEO of H₂ Global Group. “Our goal is to offer patients and physicians a gentle, accessible, and scientifically validated solution.”

The study will begin in January 2026 in cooperation with Professor David Školoudík, M.D., Ph.D., one of the Czech Republic’s leading neurologists. The six-month project aims to achieve the world’s first regulatory registration of a medical device utilizing molecular hydrogen.

About H₂ Global Group

H₂ Global Group is a European innovation group connecting research, development, manufacturing, and practical application of molecular hydrogen technologies across healthcare, wellness, sports, cosmetics, and veterinary sectors.

Under the leadership of David Maršálek, the group has built a vertically integrated ecosystem, from R&D and product innovation to manufacturing and global distribution. With an estimated company valuation exceeding USD 77 million, expanding patent portfolio, and strategic partnerships worldwide, H₂ Global Group ranks among Europe’s most progressive biotechnology innovators. For more information, visit www.H2Global.group

Source: https://apnews.com/press-release/pr-newswire/czech-breakthrough-in-medicine-h%E2%82%82-global-group-receives-regulatory-approval-for-hydrogen-clinical-study-new-era-in-alzheimers-therapy-begins-0ed2505a01c678655fef658f53f93c11?utm_source=ecomail&utm_campaign=2025_10_24_globalni_medialni_ohlas_schvaleni_klinicke_studie_sukl_posouva_h2_global_group_do_centra_&utm_medium=email&utm_term=30027&ecmid=23486

H2 Longevity®: The Czech Hydrogen-Based Longevity Revolution Conquering the World

H2 Longevity®: The Czech Hydrogen-Based Longevity Revolution Conquering the World

by | Oct 19, 2025 | Health

The Czech company H2 Global Group, a world leader in the HealthTech and MedTech sectors with more than 13 years of research and development in the field of Molecular Hydrogen®, presents its latest exclusive project – the H2 Longevity® longevity center.

 

This innovative project combines science, modern technologies, and an exclusive wellness experience into one concept that transforms how people approach health, energy, and performance.

“We are following the trend. Customers want individual care for body and mind. Our hydrogen rituals within the H2 Longevity® project are the answer to this demand. It’s a form of biohacking with hydrogen – a modern approach that uses scientifically proven methods to optimize healthy body function, regeneration, and both mental and physical performance.
We are the only ones in the world who can comprehensively, safely, and effectively combine the effects of hydrogen, science, wellness, and experience into one functional system,”
says David Maršálek, founder and CEO of H2 Global Group.

 

A new symbol of health, vitality, and longevity

H2 Longevity® Ostrava is the first next-generation longevity center and the result of many years of research and know-how by the H2 Global Group team. The goal is to build a network of similar centers worldwide in cooperation with partners and distributors.

The program is based on scientific findings and delivers measurable results — from cell regeneration and performance enhancement to slowing down the aging process and harmonizing body and mind.
The next development phase of H2 Longevity® will include diagnostic measurements that allow clients to understand their body’s condition and receive precise recommendations for personalized care.

H2 Longevity® as a lifestyle – the path to healthy longevity

The project offers a personalized approach and is designed not only for distributors and partners but also for companies that wish to provide employees with modern health and regeneration benefits through corporate wellness zones — with an emphasis on injury prevention, stress reduction, and sustainable performance.

H2 Longevity® is also ideal for sports clubs, fitness centers, beauty salons, and rehabilitation facilities seeking to offer the most advanced form of regeneration and biohacking through the correct and safe use of Molecular Hydrogen® at a global standard.

“Customers, distributors, partners, and investors understand that H2 Longevity® is not just another wellness trend but a new global wave of health, science, and exclusivity. Our goal is to connect the world under a brand that carries a Czech signature with global significance,”
adds David Maršálek.

The project already has a global dimension, and new partners from around the world are expressing interest in collaboration.
H2 Global Group’s technologies are already used by thousands of customers, clients, and distributors in the Czech Republic, Slovakia, Germany, Spain, England, the USA, and Hong Kong, and the expansion continues.

The fusion of science and functional solutions

H2 Longevity® offers H2 Ritual Collection wellness rituals combining hydrogen inhalation, red light therapy, bottled hydrogen water (H2 Premium®), nutritional supplements (H2 Brain® and H2 Forte®), and skincare treatments.

These procedures use devices developed by H2 Medical Technologies, a subsidiary of H2 Global Group, which is the exclusive supplier of professional hydrogen generators and inhalers for wellness centers, spas, private clinics, medical facilities, and even home use.

The development roadmap also includes patented hydrogen-based cosmetics, scheduled for official market launch in early 2026.
Together, these elements form a comprehensive ecosystem of body and mind care, unparalleled anywhere in the world.

H2 Global Group – a company transforming medicine

The company is also active in medical research and development.
Its subsidiary H2 Medical Technologies has developed a prototype of the world’s first medical device for controlled hydrogen therapy, designed for people with mild cognitive impairment (MCI) — a condition that often precedes Alzheimer’s dementia.
The goal is to register the device as a certified medical product and include it in public health insurance coverage in the near future.

This technology, developed under a patent by Japanese scientist Professor Shigeo Ohta, co-founder of H2 Global Group, was presented in September at the prestigious LSI Europe 2025 international conference for investors and innovators in London, where it attracted significant attention from both investors and professionals.

H2 Global Group recognizes its social responsibility, which includes bringing innovations that improve health, vitality, and quality of life for people worldwide.
At the same time, it offers opportunities for investors, partners, and distributors who want to be part of the revolution in health, science, and longevity.

“Hydrogen is the molecule of life that connects the world. We are proud that it is from the Czech Republic that we bring solutions improving the quality of life for millions of people,”
concludes David Maršálek, CEO and founder of H2 Global Group.

H2 Longevity® Center Ostrava now open to the public

The newly opened H2 Longevity® Center in Ostrava invites the general public to experience first-hand modern health and longevity technologies.
Every visitor can now enjoy a first visit free of charge and personally experience the effects of molecular hydrogen in combination with light therapy and other exclusive procedures.

Clients can later participate in regular care programs focused on performance, regeneration, and harmony of body and mind — both locally and with partner centers.
Thus, H2 Longevity® Ostrava becomes a place where the science of health transforms into personal experience.

Source:
Metro.cz – PROTEXT: H2 Longevity®: The Czech Hydrogen Longevity Revolution Conquers the World

Czech Innovation Against Alzheimer’s: H2 Global Group Enters a Key Growth Phase

Czech Innovation Against Alzheimer’s: H2 Global Group Enters a Key Growth Phase

by | Oct 2, 2025 | Alzheimer, Health, Neurology, Spa, Sport, Stomatology, Veterina

H2 Global Group, together with its subsidiary H2 Medical Technologies, has entered a decisive growth stage following strong recognition at LSI Europe 2025 in London. The group presented its breakthrough approach to preventing and treating neurodegenerative diseases, including Alzheimer’s, confirming its position among global leaders in the MedTech and HealthTech sectors.

At the core of this innovation is a prototype medical device for controlled hydrogen therapy, developed by H2 Medical Technologies. The device is designed for patients with mild cognitive impairment, a condition that often precedes Alzheimer’s. Non-invasive and suitable for both clinical and home use, it is based on a patented method pioneered by a Japanese team led by Professor Shigeo Ohta, co-owner of H2 Global Group. Research indicates that molecular hydrogen can protect brain cells, slow inflammation, and support neuronal metabolism and connectivity.

“Hydrogen is the smallest molecule in the universe, yet it can protect our most valuable assets – memory and independence,” explains Prof. Ohta.

Group founder David Maršálek, who has been developing hydrogen technologies since 2011, adds: “Our mission is to launch the world’s first hydrogen-based medical device for Alzheimer’s prevention and therapy support. With strong scientific evidence, patent protection, and an experienced team, we are positioned to succeed.”

Between 2021 and 2025, H2 Global Group raised over $18M in Seed funding, built a network of 20,000 end-customers and 50+ B2B partners, and exceeded revenues of circa $7.4M. Current transactions value the group at circa $77M.

Now entering Series A, the group plans to raise $25–30 million to fund global expansion into Europe, the U.S., the Middle East, and Africa, complete clinical trials, and secure EU and FDA registrations. Revenue projections forecast growth to nearly $48M by 2029.

The portfolio extends beyond the medical device. H2 Medical Technologies supplies hydrogen generators and therapeutic systems to spas, sports clubs, physiotherapy practices or dental clinics. Its solutions are also approved for veterinary use. In parallel, H2 Pharm develops consumer products such as H2 Premium Water®, H2 Brain®, H2 Forte®, and H2 Dent Care®, which are commercially successful and distributed via e-commerce and a B2B network.

“Such opportunities are rare,” concludes Maršálek. “When future textbooks are written, our investors will say: I was there. Hydrogen is not only energy source but a molecule of lifeconnecting the world. Invest in Hydrogen!”

Source: ap.news.com

Czech MedTech Startup H2 Medical Technologies Unveils World’s First Patented Hydrogen-Based Therapy with the Potential to Target Alzheimer’s Disease

Czech MedTech Startup H2 Medical Technologies Unveils World’s First Patented Hydrogen-Based Therapy with the Potential to Target Alzheimer’s Disease

by | Oct 2, 2025 | Alzheimer, Health, Neurology, Spa, Sport, Stomatology, Veterina

H2 Medical Technologies, part of the H2 Global Group, has developed the world’s first functional hydrogen-based therapy medical device prototype for clinical trials — aimed at both preventing and treating Alzheimer’s disease.

Today, more than 6.5 million Americans and 50 million people worldwide are living with Alzheimer’s and other forms of dementia. According to the World Health Organization, this number could triple by 2050, placing an immense burden on families and healthcare systems. Despite decades of research, no effective solution has been found — until now.

“This is not another experiment — it is the first technology in the world with the potential to prevent Alzheimer’s disease before it even starts, while supporting those already affected,” says David Marsalek, founder and CEO of H2 Global Group. The company believes its effectiveness will be further confirmed in an upcoming new clinical trial. “Our mission is clear: to turn decades of research into real hope for millions of families around the world. We are part of a strong vision of a society where hydrogen is the molecule of life that connects the world.”

From the Lab to the Global Stage

H2 Global Group will present this breakthrough at LSI Europe 2025 in London, one of the world’s most prestigious MedTech and HealthTech conferences. The project builds on 30+ years of research and patents developed with Professor Shigeo Ohta, a global leader in molecular hydrogen science and co-founder of H2 Global Group.

More Than Medicine: A New Era of Brain Health

While the immediate focus is Alzheimer’s, potential applications extend to neurological disorders, brain regeneration, and healthy aging.

Alongside its medical device, H2 Global Group has launched consumer products such as H2 Premium Water® and H2 Brain®, a world-first two-phase dietary supplement that stimulates molecular hydrogen production through the gut microbiome. The company is also the only certified global manufacturer authorized to use hydrogen-based medical devices in veterinary medicine.

Today, its hydrogen-based solutions are already being adopted by wellness centers, rehabilitation clinics, dental practices, and elite sports organizations across Europe — underscoring the broad potential of the technology.

An Opportunity for Visionary Investors

Until now, the project has been funded primarily by Czech investors. H2 Global Group is now opening the door to U.S. and global partners at a critical growth stage, with EU registration underway and FDA approval next on the horizon — unlocking the world’s largest healthcare market.

The global Alzheimer’s therapeutics market is projected to exceed $20 billion by 2030, with dementia-related costs already surpassing $1 trillion annually. Positioned as the only functional hydrogen-based therapy of its kind, H2 Global Group offers investors a rare first-mover advantage in one of the most urgent and lucrative markets of our time.

Source: finance.yahoo.com

H2 Brain®: Innovative Support for Mental Well-being at the Cellular Level

H2 Brain®: Innovative Support for Mental Well-being at the Cellular Level

by | Mar 19, 2025 | Alzheimer, Health

H2 Vibe proudly introduces H2 Brain®, an innovative food supplement developed to support mental wellbeing and cognitive performance – both during the day and at night. This unique two-phase formulation respects the body’s natural circadian rhythm and is carefully tailored to meet the brain’s changing needs throughout the day.

Today’s fast-paced lifestyle, combined with a lack of physical activity and chronic stress, is taking a toll on our mental health. “People today live under immense pressure, which often results in poor sleep quality and a general sense of mental unease,” explains Viktória Procházková, CEO of H2 Global Group. “At the same time, data indicates a growing prevalence of neurological disorders, which motivated us to develop a comprehensive solution aimed at supporting cognitive function and emotional balance.”

For nearly a year, the Czech company H2 Global Group fine-tuned the formula to perfection – resulting in H2 Brain®, a two-phase supplement designed to meet the brain’s essential needs and promote mental clarity and emotional resilience. “Throughout the development of H2 Brain®, we paid close attention to the bioavailability and synergistic interactions of each ingredient to achieve maximum efficacy at the cellular level,” adds PharmDr. Milan Krajíček, Head of Research and Production at H2 Pharm.

Targeted Support – Day and Night

H2 Brain® has been developed as a two-phase system to address the brain’s distinct daytime and nighttime needs. The morning tablet is focused on enhancing concentration and cognitive performance throughout the day. It includes Baikal skullcap extract, astaxanthin, and selenium with sustained release properties. The evening tablet, by contrast, is formulated to encourage mental relaxation and restorative sleep, with ingredients such as taurine, B vitamins, and ginkgo biloba.

H2 Brain® also features the patented HydrogenIQ complex, which naturally supports the production of molecular hydrogen. As the smallest molecule in the universe, molecular hydrogen is currently being explored for its unique ability to cross the blood–brain barrier and reach brain cells. Research suggests it may play a beneficial role in promoting cellular regeneration and protecting neurons against oxidative stress.

For Students, Professionals, Parents and Seniors

H2 Brain® is designed for a wide range of individuals – from students seeking to boost focus during intensive study, to professionals and parents managing high cognitive loads, to older adults looking to support mental clarity and cognitive longevity. “Our aim with H2 Brain® was to create a supplement that actively supports brain function and contributes to long-term mental wellbeing,” concludes Krajíček.

According to the World Health Organization (WHO), approximately 55 million people worldwide are currently living with dementia, with around 10 million new cases diagnosed each year. Alzheimer’s disease accounts for 60–70% of these cases. By 2050, the global number of people affected by dementia is expected to rise to 139 million. This alarming trend highlights the urgent need for proactive measures to support brain health from midlife onwards.

Molecular hydrogen and oxidative stress reduction

Molecular hydrogen and oxidative stress reduction

by | Mar 6, 2025 | Health, Neurology

Imagine oxidative stress as an invisible enemy silently damaging your body. Free radicals attack your cells, while your natural antioxidants struggle to keep up. This internal chaos can lead to serious conditions such as heart disease, cancer, and accelerated ageing. Fortunately, molecular hydrogen (H₂) offers a solution—acting as a selective antioxidant that targets the most harmful free radicals and supports health at the cellular level.

Molecular Hydrogen as a Selective Antioxidant

Molecular hydrogen is unique in its ability to selectively neutralise the most dangerous free radicals, such as the hydroxyl radical (•OH), without interfering with beneficial oxidative processes that are essential to the body’s function. This selective action makes molecular hydrogen a powerful ally in combating oxidative stress without disrupting normal cellular activity.

Groundbreaking Research by Professor Shigeo Ohta

The first major scientific study to highlight the potential of molecular hydrogen in medicine was published in 2007 by Japanese biochemist Professor Shigeo Ohta in the prestigious journal Nature Medicine. The study showed that inhaling molecular hydrogen significantly reduced oxidative stress-induced cellular damage in animal models. This landmark discovery sparked widespread scientific interest in the therapeutic potential of molecular hydrogen.

Further Studies and Clinical Evidence

Since Professor Ohta’s publication, numerous studies have confirmed the efficacy of molecular hydrogen in reducing oxidative stress. For example, research published in the Journal of Clinical Biochemistry and Nutrition demonstrated that drinking hydrogen-rich water reduced markers of oxidative stress in patients with metabolic syndrome.

Another study, published in the Journal of Neurochemistry, found that molecular hydrogen could protect brain cells from oxidative damage and inflammation—suggesting its potential in preventing and treating neurodegenerative diseases such as Alzheimer’s disease.

Clinical trials have also shown benefits for patients with rheumatoid arthritis, coronary artery disease, and even for athletes exposed to high levels of oxidative stress due to intense physical activity.

Image: Molecular hydrogen shows promise in the treatment and prevention of Alzheimer’s and other neurodegenerative conditions.
Photo credit: Shutterstock

Mechanisms of Action

Molecular hydrogen acts not only as a selective antioxidant, but also as a signalling molecule that influences various biochemical pathways in the body. For instance, it activates the Nrf2 pathway, which regulates the expression of antioxidant enzymes and enhances the body’s natural defences against oxidative stress. Moreover, molecular hydrogen is believed to modulate inflammatory responses, which is significant in the treatment of chronic inflammatory diseases.

A Promising Step Towards Better Health

Molecular hydrogen is emerging as a highly promising tool for reducing oxidative stress and protecting cells from associated damage. Backed by scientific and clinical research, its use is increasingly gaining recognition not only among medical professionals but also the wider public. While further studies are still needed, existing evidence suggests that molecular hydrogen could play a vital role in the prevention and treatment of a wide range of conditions linked to oxidative stress.

Header image source: Shutterstock

H2 Global Group
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.